This observational study sponsored by Superior University aims to enhance the understanding of both conventional and non-conventional cardiovascular risk factors associated with ACS. The findings could lead to improved risk assessment tools and personalized interventions, potentially creating a competitive edge in the cardiovascular therapeutics market. Given the increasing focus on non-conventional risk factors, this research may position the sponsor favorably in a market that is evolving towards more holistic cardiovascular risk management strategies. The study's outcomes could attract interest from pharmaceutical companies looking to develop novel therapies or risk assessment tools targeting ACS.